Intraaticular treatment of tarsal degenerative joint disease in cattle.
Tarsal degenerative joint disease (DJD) in 12 cattle was classified as primary or secondary, based on age, evidence of hereditary or congenital joint conformation defects, faulty hindlimb alignment, duration and type of usage joints were subjected to, and history or signs of repeated trauma. Three of the cattle had bilateral primary tarsal DJD, 7 had bilateral secondary tarsal DJD, and 2 had secondary DJD of the left tarsus. Analyses of synovial fluid samples provided a means of characterizing pathologic changes of tarsal DJD, Results of blood and synovial fluid analyses were grouped in compilation of data for cattle affected with either primary or secondary tarsal DJD. Corticosteroids and a long-acting synthetic progestational agent were injected singly or in combination with aqueous antibiotics into affected tarsal joints. Tarsal joints of 5 of the cattle responded favorably to a single intraarticular treatment, as manifested by palliative relief and functionally usable joints. Seven joints of 5 cattle were subjected to repeated intraarticular treatment. Serial synovial fluid analyses in 7 of the cattle provided a means of assessing tarsal joint response to intraarticular treatment or to therapeutic arthrocentesis, exclusive of patient objective response. One cow developed a mild self-limiting bilateral postinjection synovitis that was resolved after the 2nd and final intraarticular injection. Usable function returned to tarsal joints of cattle that responded favorably to intraarticular treatment at different periods after single or repeated injections. Three cattle with advanced tarsal DJD experienced minor temporary relief and were euthanatized at their owner's request. Improvement did not occur in the tarsal joint of 1 cow subjected to therapeutic aspiration only. Intraarticular treatment in all cattle was considered supportive to the animal's well-being rather than curative.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001786:Blood Glucose / Q000032:analysis; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy*; D004096:Dihydrostreptomycin Sulfate / Q000627:therapeutic use; D005260:Female; D005477:Fluprednisolone / Q000627:therapeutic use; D005947:Glucose / Q000032:analysis; D007269:Injections, Intra-Arterial; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D009355:Neomycin / Q000627:therapeutic use; D010003:Osteoarthritis / Q000188:drug therapy / Q000662:veterinary*; D010406:Penicillins / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage; D011506:Proteins / Q000032:analysis; D013582:Synovial Fluid / Q000032:analysis / Q000166:cytology / Q000201:enzymology; D013640:Tarsal Joints; D014783:Viscosity
D000900:Anti-Bacterial Agents; D001786:Blood Glucose; D010406:Penicillins; D011506:Proteins; D005477:Fluprednisolone; D011239:Prednisolone; D008525:Medroxyprogesterone; D009355:Neomycin; D005947:Glucose; D004096:Dihydrostreptomycin Sulfate; D008775:Methylprednisolone